FDA approves gabapentin prodrug as restless legs treatment

Thompson, Cheryl A.
May 2011
American Journal of Health-System Pharmacy;5/15/2011, Vol. 68 Issue 10, p862
Academic Journal
No abstract available.


Related Articles

  • FDA actions.  // Primary Care Reports;Jun2011 Pharmacology Watch, p2 

    The article presents several approvals by the U.S. Food and Drug Administration (FDA) including rituximab for treating Wegener's granulomatosis and microscopic polyangiitis and ganapentin enacarbil for treating moderate-to-severe restless leg syndrome.

  • UCB Hits FDA Roadblock in sNDA for Wider Label. Young, Donna // BioWorld International;12/24/2008, Vol. 13 Issue 52, p5 

    The article reports on the response letter received by UCB SA from the U.S. Food and Drug Administration (FDA) to its supplemental new drug application to expand the labeling for Neupro. Neupro is intended to treat symptoms of advanced Parkinson's disease and primary restless legs syndrome. The...

  • GSK Treatment For Restless Leg Syndrome Receives OK.  // Chain Drug Review;4/25/2011, Vol. 33 Issue 8, p218 

    The article reports on the approval of Horizant, a treatment for primary restless legs syndrome (RLS) in adults from GlaxoSmithKline PLC and XenoPort Inc., by the U.S. Food and Drug Administration (FDA) in 2011.

  • Treating Restless Legs Syndrome. Rados, Carol // FDA Consumer;May/Jun2006, Vol. 40 Issue 3, p26 

    The article provides information on the Restless Legs Syndrome (RLS). Requip was approved by the U.S. Food and Drug Administration in May 2005 for the treatment of the condition. RLS, if left untreated, causes exhaustion and daytime fatigue, affecting a person's quality of life. The cause of RLS...

  • New indication for Requip calms restless legs.  // Drug Topics;5/16/2005, Vol. 149 Issue 10, p6 

    This article reports that the U.S. Food and Drug Administration has approved GlaxoSmithKline PLC's Ropinirole drug for the treatment of moderate to severe primary restless legs syndrome in adults.

  • FDA actions. Elliott, William T. // Clinical Oncology Alert;Jun2011 Supplement 2, p2 

    The article offers information on the Food and Drug Administration (FDA) actions that include the approval of rituximab (marketed as Rituxan by Genentech) for the treatment of Wegener's granulomatosis and microscopic polyangiitis; and the approval of gabapentin enacarbil extended-release tablets...

  • The status of rotigotine as a safe and effective alternative in the treatment of restless legs syndrome. Bourgeois, Pascale; Frenette, Eric // Research & Reports in Transdermal Drug Delivery;2013, Vol. 2, p1 

    Restless legs syndrome (RLS) is characterized by an urge to move the legs that occurs mainly with inactivity, and it is relieved by movement and is usually worse by the end of the day. It is highly prevalent, affecting 1.9% to 4.5% of the population, and although its etiology is uncertain,...

  • Expert Sees More 505(B)(2) Filings on the 'Horizant'. Morrison, Trista // BioWorld Insight;9/12/2011, Vol. 19 Issue 37, p1 

    The article reports that drug Horizant for the treatment of restless legs syndrome by XenoPort Inc. and partner GlaxoSmithKline PLC was originally developed and submitted for U.S. Food & Drug Administration (FDA) via the 505 (B)(1). It explains that the traditional B1 path is for new drugs while...

  • UCB receives FDA approval for Parkinson's and restless legs syndrome treatment.  // PharmaWatch: CNS;May2012, Vol. 11 Issue 5, p5 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of UCB's Neupro which is a rotigotine transdermal system for treating Parkinson's disease (PD) and restless legs syndrome (RLS) in 2012. It indicates that Neupro is capable of stimulating dopamine receptors within...

  • More drugs hobble restless legs syndrome. Karpa, Kelly Dowhower // Drug Topics;6/4/2007, Vol. 151 Issue 11, p20 

    The article reports on several drugs that were approved for the treatment of restless legs syndrome (RLS) by the U.S. Food and Drug Administration (FDA). Ropinirole from GlaxoSmithKline became the first drug approved by FDA for RLS followed by pramipexole from Boehringer Ingelheim. Xenoport Inc....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics